<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15203718</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>06</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>12</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0953-7104</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>15</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Platelets</Title>
                <ISOAbbreviation>Platelets</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.</ArticleTitle>
            <Pagination>
                <MedlinePgn>167-72</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We evaluated the plasma concentrations of platelet activation markers, microparticles and soluble adhesion molecules in patients with arteriosclerosis obliterans (ASO) and compared the beneficial effects of cilostazol alone and combination therapy of cilostazol and dipyridamole in these patients. There was a significant elevation of CD62P, CD63, PAC-1, annexin V, platelet-derived microparticles (PDMPs), sP-selectin, sE-selectin, sICAM-1 and sVCAM-1 in the ASO patients compared with the controls. Platelet aggregation was decreased by 2 weeks of cilostazol monotherapy in the ASO patients. Adding dipyridamole to the cilostazol therapy for 2 weeks further reduced platelet aggregation. While treatment with cilostazol alone reduced levels of CD62P, CD63, PAC-1, annexin V, PDMP, and sP-selectin, the combination therapy reduced these parameters further. While sE-selectin and cell adhesion molecules did not change significantly after 2 weeks of combination therapy, they exhibited a remarkable decrease after 16 weeks of combination treatment. These findings suggest that platelets are activated in ASO patients, and cilostazol is effective to reduce platelet activation. Furthermore, dipyridamole may potentiate the beneficial effect of cilostazol in ASO patients. Combination use of both drugs may help to prevent the onset of cardiovascular complications in patients with ASO by activated platelets and PDMP.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nomura</LastName>
                    <ForeName>Shosaku</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>First Department of Internal Medicine, Kansai Medical University, 10-15 Fumizonocho, Moriguchi, Osaka 570-8507, Japan. shosaku-n@mbp.ocn.ne.jp</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inami</LastName>
                    <ForeName>Norihito</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iwasaka</LastName>
                    <ForeName>Toshiji</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yongge</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Clinical Trial</PublicationType>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Platelets</MedlineTA>
            <NlmUniqueID>9208117</NlmUniqueID>
            <ISSNLinking>0953-7104</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Cell Adhesion Molecules</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance>Tetrazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>64ALC7F90C</RegistryNumber>
                <NameOfSubstance>Dipyridamole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N7Z035406B</RegistryNumber>
                <NameOfSubstance>cilostazol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Arteriosclerosis Obliterans</DescriptorName>
                <QualifierName MajorTopicYN="Y">blood</QualifierName>
                <QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName>
                <QualifierName MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Dipyridamole</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Particle Size</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Platelet Activation</DescriptorName>
                <QualifierName MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N">Tetrazoles</DescriptorName>
                <QualifierName MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15203718</ArticleId>
            <ArticleId IdType="doi">10.1080/09537100410001682779</ArticleId>
            <ArticleId IdType="pii">R51EWLTH0RCJ4B8C</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
